25 related articles for article (PubMed ID: 38430581)
21. Long-term di-(2-ethylhexyl) phthalate exposure reduces sorafenib treatment efficacy by enhancing mesenchymal transition in hepatocellular carcinoma.
Shih MS; Suk FM; Chiu WC; Lee CY; Hsu FY; Liao YJ
Ecotoxicol Environ Saf; 2024 Mar; 273():116161. PubMed ID: 38430581
[TBL] [Abstract][Full Text] [Related]
22. The impact of Di-(2-ethylhexyl) Phthalate and Mono(2-ethylhexyl) Phthalate in placental development, function, and pathophysiology.
Martínez-Razo LD; Martínez-Ibarra A; Vázquez-Martínez ER; Cerbón M
Environ Int; 2021 Jan; 146():106228. PubMed ID: 33157377
[TBL] [Abstract][Full Text] [Related]
23. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.
Doull J; Cattley R; Elcombe C; Lake BG; Swenberg J; Wilkinson C; Williams G; van Gemert M
Regul Toxicol Pharmacol; 1999 Jun; 29(3):327-57. PubMed ID: 10388618
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
[TBL] [Abstract][Full Text] [Related]
25. Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk.
Huber WW; Grasl-Kraupp B; Schulte-Hermann R
Crit Rev Toxicol; 1996 Jun; 26(4):365-481. PubMed ID: 8817083
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
